



For the treatment of AML in patients 70 and older...

Now, for the first time

She has a fighting chance

INTRODUCING NEW ZARNESTRA, because the golden years are worth the fight. Now deliver survival gains in an area of high unmet need.

- Designed for the unique disease biology and clinical aspects of AML in patients 70 and older
- 26% improvement in survival vs best supportive care
- Well tolerated
- Oral formulation allows for outpatient treatment

 **Zarnestra[®]**
Tipifarnib Tablets

A unique course of action